MarketScreener Strategies Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq 23:00:00 11/09/2026 +03			5-day change	1st Jan Change
32.47 ^USD	+0.74%		-3.36%	+5.42%

09-08	Espiria Hållbar Framtid rose 4.5 percent in August, Vestas and Hansa Biopharma made positive contributions	FW
09-08	Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN	FW

	Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course	August 07, 2026 at 04:12 pm
	Genmab soars after raising its guidance	August 07, 2026 at 11:00 am
	Genmab rebounds on a European Commission decision	July 07, 2026 at 10:52 am
	Genmab: Financing weighs now, pipeline pays later	June 23, 2026 at 02:20 pm
	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis	May 09, 2026 at 03:05 pm
	Genmab: 2025 miss and cautious 2026 targets erode investor confidence	February 18, 2026 at 05:09 pm
	Genmab advances on earnings strength and pipeline while lower valuation opens upside	November 07, 2025 at 06:01 pm
	Genmab: A bold shift from defensive to aggressive	September 29, 2025 at 05:45 pm
	Genmab: From now on, courage to the most patient	April 01, 2025 at 05:57 pm